The Cambridge, Mass.-based pharmaceutical company is developing treatments for eye diseases. The company raised $50 million in an offering of 5 million shares at $10 each. The stock priced below the expected range of $13 to $15. Eleven plans to use the proceeds to fund the next phase of a drug trial. Shares, trading under the symbol "EBIO," rose 85 cents, or 8.5 percent, to $10.85 on the Nasdaq.
Description
Eleven Biotherapeutics, Inc., is a United States-based company, which develops protein-based biotherapeutics. The Company engages in engineering and developing protein-based therapeutics to treat inflammatory conditions, coagulation disorders, and muscle wasting conditions. Its molecular understanding of clinical effects to create protein-based medicines helps to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders and muscle wasting conditions.
Address
SUITE 400, 215 FIRST STREET
CAMBRIDGE, MA 02142
United States
CAMBRIDGE, MA 02142
United States
Key stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -613.02% | - |
| Operating margin | -569.13% | - |
| EBITD margin | - | - |
| Return on average assets | -221.81% | -323.09% |
| Return on average equity | - | - |
| Employees | 16 |
No comments:
Post a Comment